Global Geriatric Medicine Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapeutics;

Analgesic, Antihypertensive, Statins, Antidiabetic, PPI, Anticoagulant, Antipsychotic, and Others.

By Form;

Tablet, Liquid, Capsule, Inhalers, Topical, and Others.

By Disease Indication;

Oncology, Orthopedic Disorders, Cardiovascular Disorders, Respiratory Disorders, Neurological Disorders, Metabolic Disorders, and Others.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn717856971 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Geriatric Medicine Market (USD Million), 2021 - 2031

In the year 2024, the Global Geriatric Medicine Market was valued at USD 339,034.93 million. The size of this market is expected to increase to USD 464,479.16 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.6%.

The global geriatric medicine market is expanding rapidly due to the increasing elderly population worldwide and the rising prevalence of age-related health conditions. As life expectancy increases, more individuals are living into old age, leading to a growing demand for medical care tailored specifically to the elderly. This population is particularly susceptible to chronic conditions such as cardiovascular diseases, diabetes, arthritis, dementia, and osteoporosis, creating a need for specialized medical treatments and therapies. The market for geriatric medicine is therefore being driven by both the rising number of elderly individuals and the need for specialized treatments that address the complex health issues commonly faced by older adults.

One of the key factors contributing to the growth of the geriatric medicine market is the advancements in pharmaceutical treatments and the development of new therapies targeting age-related diseases. There is a growing focus on drug discovery and innovations in areas such as Alzheimer’s disease, Parkinson’s disease, and cancer treatments, all of which disproportionately affect the elderly population. Additionally, the use of personalized medicine and precision therapeutics has gained momentum, enabling healthcare providers to offer more tailored treatments for elderly patients based on their genetic makeup and specific health conditions. As research and development efforts in geriatric pharmacology continue to progress, the availability of new, effective therapies is likely to accelerate the growth of the market.

Geographically, North America dominates the global geriatric medicine market, supported by its advanced healthcare infrastructure, high healthcare spending, and the significant aging population in countries like the United States and Canada. Europe also represents a substantial market share, driven by an aging demographic and increasing government investments in geriatric healthcare services. However, the Asia-Pacific region is expected to witness the highest growth rate in the coming years due to rapidly aging populations in countries like Japan, China, and India, along with expanding healthcare access. As awareness of geriatric health issues increases and healthcare systems improve, emerging markets in Latin America and the Middle East are also contributing to the market’s growth. This broad global demand for geriatric medicine underscores the increasing recognition of the unique healthcare needs of the aging population.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapeutics
    2. Market Snapshot, By Form
    3. Market Snapshot, By Disease Indication
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Global Geriatric Medicine Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
      2. Restraints
      3. Opportunities
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Geriatric Medicine Market, By Therapeutics, 2021 - 2031 (USD Million)
      1. Analgesic
      2. Antihypertensive
      3. Statins
      4. Antidiabetic
      5. PPI
      6. Anticoagulant
      7. Antipsychotic
      8. Others
    2. Global Geriatric Medicine Market, By Form, 2021 - 2031 (USD Million)
      1. Tablet
      2. Liquid
      3. Capsule
      4. Inhalers
      5. Topical
      6. Others
    3. Global Geriatric Medicine Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Oncology
      2. Orthopedic Disorders
      3. Cardiovascular Disorders
      4. Respiratory Disorders
      5. Neurological Disorders
      6. Metabolic Disorders
      7. Others
    4. Global Geriatric Medicine Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies,
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Global Geriatric Medicine Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. GlaxoSmithKline Plc
      2. Boehringer Ingelheim GmbH
      3. Novartis AG
      4. Bristol-Myers Squibb Company
      5. Pfizer Inc
      6. Eli Lilly Company
      7. Abbott Laboratories Inc
  7. Analyst Views
  8. Future Outlook of the Market